amp biosimilars AG Successfully Out-Licenses First Biosimilar
- First out-licensing of an oncology biosimilar from the ampb product pipeline
- Partner to finance development and market authorization
- Partner to receive rights for China; rights for the rest of the world remain with ampb
Hamburg, Germany, May 28, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced its first successful out-licensing of a biosimilar. The first biosimilar to be out-licensed from the product pipeline is ABY-018, a humanized monoclonal antibody. At present, there are four biosimilars in the ampb product pipeline.
amp biosimilars licensed the biosimilar to a leading mid-sized Chinese pharmaceutical corporation, with a portfolio of more than 50 pharmaceutical products, a GMP-certified production capacity of two billion tablets and one billion capsules per year as well as a national sales network that puts it in an excellent position to pursue commercialization in China.
The partner will assume all financing for the development and market approval processes starting from Clinical Phase I through to production and marketing of the biosimilar in China. The partner will have the right to unlimited marketing in China and shall pay a percentage of the proceeds to amp biosimilars (royalties). amp biosimilars retains the global rights outside of China. This arrangement allows amp biosimilars to conclude additional out-licensing agreements for the biosimilar, for example in the US, Europe and other Asian countries, or to develop the relevant markets independently and thus generate greater potential revenues. By way of reciprocation, ampb will pay the Chinese partner royalties in the same amount.
"Our team is very happy with this outcome. We have just cleared a decisive hurdle, validating the strength of our business model," says Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. "By out-licensing to China, we are not only tapping into the potential represented by this rapidly expanding market, but also have the opportunity of forming partnerships with companies in other markets outside of China. This represents a great step forward - with others soon to follow."
This out-licensing of its first biosimilar also marks amp biosimilar's successful market launch in China. In the course of this, the company benefits from the intensive work and the extensive network that was set up in recent years. The Chinese pharmaceutical market is currently the second largest in the world and has been growing in the past by up to 25 percent per year. By 2020 the pharmaceutical market is expected to have a volume of 1 trillion US dollars. The Chinese biosimilar market may actually be the largest in the world by 2017, surpassing Europe.
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com.
Contact:
MC Services AG
Fabian Lorenz
T +49 211 529252-28
Email: fabian.lorenz@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
- Partner to finance development and market authorization
- Partner to receive rights for China; rights for the rest of the world remain with ampb
Hamburg, Germany, May 28, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced its first successful out-licensing of a biosimilar. The first biosimilar to be out-licensed from the product pipeline is ABY-018, a humanized monoclonal antibody. At present, there are four biosimilars in the ampb product pipeline.
amp biosimilars licensed the biosimilar to a leading mid-sized Chinese pharmaceutical corporation, with a portfolio of more than 50 pharmaceutical products, a GMP-certified production capacity of two billion tablets and one billion capsules per year as well as a national sales network that puts it in an excellent position to pursue commercialization in China.
The partner will assume all financing for the development and market approval processes starting from Clinical Phase I through to production and marketing of the biosimilar in China. The partner will have the right to unlimited marketing in China and shall pay a percentage of the proceeds to amp biosimilars (royalties). amp biosimilars retains the global rights outside of China. This arrangement allows amp biosimilars to conclude additional out-licensing agreements for the biosimilar, for example in the US, Europe and other Asian countries, or to develop the relevant markets independently and thus generate greater potential revenues. By way of reciprocation, ampb will pay the Chinese partner royalties in the same amount.
"Our team is very happy with this outcome. We have just cleared a decisive hurdle, validating the strength of our business model," says Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. "By out-licensing to China, we are not only tapping into the potential represented by this rapidly expanding market, but also have the opportunity of forming partnerships with companies in other markets outside of China. This represents a great step forward - with others soon to follow."
This out-licensing of its first biosimilar also marks amp biosimilar's successful market launch in China. In the course of this, the company benefits from the intensive work and the extensive network that was set up in recent years. The Chinese pharmaceutical market is currently the second largest in the world and has been growing in the past by up to 25 percent per year. By 2020 the pharmaceutical market is expected to have a volume of 1 trillion US dollars. The Chinese biosimilar market may actually be the largest in the world by 2017, surpassing Europe.
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com.
Contact:
MC Services AG
Fabian Lorenz
T +49 211 529252-28
Email: fabian.lorenz@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.